Media

A Topical Dual-PI3K/mTOR inhibitor, in healthy volunteers followed by patients with the Rare Disease “Cutaneous T-Cell Lymphoma” in collaboration with the CHDR, LUMC, and SCARLETRED. Company Started Treatment of Healthy...

The Board of Directors of PIQUR Therapeutics AG is pleased to announce the appointment of Dr. Melanie Rolli as Chief Executive Officer with immediate effect. Dr. Rolli joined PIQUR in...

Open-label, single arm, two-stage study, evaluating the efficacy and safety of bimiralisib in patients with recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) harboring NOTCH1 loss of function...

SILVER SPRING, Md., Nov. 29, 2018 /PRNewswire/ — Today, the Tuberous Sclerosis Alliance (TS Alliance) announced a new staff member to drive its tuberous sclerosis complex (TSC) Preclinical Consortium.  Dean Aguiar, PhD, has joined...

Professor Michael N. Hall from the Biozentrum of the University of Basel receives the Lasker Basic Medical Research Award 2017 – one of the most distinguished honors in biomedical research....

PIQUR Therapeutics AG, a Swiss clinical-stage pharmaceutical company, announced today that the European Medicines Agency (EMA) has granted orphan drug designation to PIQUR’s lead compound PQR309 for the treatment of...

Dr. Melanie Rolli joins PIQUR as new Chief Medical Officer PIQUR Therapeutics AG, a Swiss clinical-stage pharmaceutical company, announced today that it has strengthened its management team with the appointment...

PIQUR Therapeutics AG, a Swiss clinical-stage pharmaceutical company, and Pierre Fabre, the second largest private French pharmaceutical group announced today that they have signed a collaboration agreement for the development...